Evidence map›Paper›PMID 39217987›Full record

ArticleImmunity2024

Meningeal lymphatic function promotes oligodendrocyte survival and brain myelination.

Sofia P das Neves, Nickoleta Delivanoglou, Yingxue Ren, Chiara Starvaggi Cucuzza, Mateusz Makuch, Francisco Almeida, Guadalupe Sanchez, Megan J Barber, Shanon Rego, Racquelle Schrader and 7 more

Abstract read
In one paragraph

Article in Immunity, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors.

Sofia P das NevesDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.
Nickoleta DelivanoglouDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.
Yingxue RenDepartment of Quantitative Health Sciences, Mayo Clinic, Jacksonville, FL 32224, USA.
Chiara Starvaggi CucuzzaDepartment of Clinical Neuroscience, Karolinska Institutet, Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden; Centre for Neurology, Academic Specialist Center, Stockholm Health Services, Stockholm, Sweden.
Mateusz MakuchOxford Autoimmune Neurology Group, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
Francisco AlmeidaLife and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Campus Gualtar, 4710-057 Braga, Portugal; ICVS/3B's - PT Government Associate Laboratory, Braga, Guimarães, Portugal.
Guadalupe SanchezDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA; Neuroscience Ph.D. Program, Mayo Clinic Graduate School of Biomedical Sciences, Mayo Clinic, Jacksonville, FL 32224, USA.
Megan J BarberDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.
Shanon RegoDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA; Post-baccalaureate Research Education Program, Mayo Clinic Graduate School of Biomedical Sciences, Mayo Clinic, Jacksonville, FL 32224, USA.
Racquelle SchraderDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA; Post-baccalaureate Research Education Program, Mayo Clinic Graduate School of Biomedical Sciences, Mayo Clinic, Jacksonville, FL 32224, USA.
Ayman H FaroqiDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA; Neuroscience Ph.D. Program, Mayo Clinic Graduate School of Biomedical Sciences, Mayo Clinic, Jacksonville, FL 32224, USA.
Jean-Leon ThomasDepartment of Neurology, Yale University School of Medicine, New Haven, CT, USA; Paris Brain Institute, Université Pierre et Marie Curie Paris 06 UMRS1127, Sorbonne Université, Paris Brain Institute, Paris, France.
Pamela J McLeanDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA; Neuroscience Ph.D. Program, Mayo Clinic Graduate School of Biomedical Sciences, Mayo Clinic, Jacksonville, FL 32224, USA.
Tiago Gil OliveiraLife and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Campus Gualtar, 4710-057 Braga, Portugal; ICVS/3B's - PT Government Associate Laboratory, Braga, Guimarães, Portugal; Department of Neuroradiology, Hospital de Braga, 4710-243 Braga, Portugal.
Sarosh R IraniOxford Autoimmune Neurology Group, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK; Department of Clinical Neurology, John Radcliffe Hospital, Oxford, UK.
Fredrik PiehlDepartment of Clinical Neuroscience, Karolinska Institutet, Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden; Centre for Neurology, Academic Specialist Center, Stockholm Health Services, Stockholm, Sweden.
Sandro Da MesquitaDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA; Neuroscience Ph.D. Program, Mayo Clinic Graduate School of Biomedical Sciences, Mayo Clinic, Jacksonville, FL 32224, USA. Electronic address: damesquita@mayo.edu.

Funding

Research Education ComponentP30AG062677 · NIA · MAYO CLINIC ROCHESTER · PI KEJAL KANTARCI · 2019 to 2026
$33.5M
Role of apoE-mediated meningeal lymphatic remodeling in the pathophysiology of Alzheimer’s diseaseRF1AG080556 · NIA · MAYO CLINIC JACKSONVILLE · PI DA MESQUITA, SANDRO · 2023 to 2023
$2.3M
Medical Research Council MR/V007173/1NIA NIH HHS P30 AG062677NIA NIH HHS RF1 AG080556Wellcome TrustWellcome Trust 104079/Z/14/Z
6 · The paper itself

Abstract

The precise neurophysiological changes prompted by meningeal lymphatic dysfunction remain unclear. Here, we showed that inducing meningeal lymphatic vessel ablation in adult mice led to gene expression changes in glial cells, followed by reductions in mature oligodendrocyte numbers and specific lipid species in the brain. These phenomena were accompanied by altered meningeal adaptive immunity and brain myeloid cell activation. During brain remyelination, meningeal lymphatic dysfunction provoked a state of immunosuppression that contributed to delayed spontaneous oligodendrocyte replenishment and axonal loss. The deficiencies in mature oligodendrocytes and neuroinflammation due to impaired meningeal lymphatic function were solely recapitulated in immunocompetent mice. Patients diagnosed with multiple sclerosis presented reduced vascular endothelial growth factor C in the cerebrospinal fluid, particularly shortly after clinical relapses, possibly indicative of poor meningeal lymphatic function. These data demonstrate that meningeal lymphatics regulate oligodendrocyte function and brain myelination, which might have implications for human demyelinating diseases.

Indexed as

BrainLymphatic VesselsMeningesMultiple SclerosisMyelin SheathOligodendrogliaAdaptive ImmunityAnimalsCell SurvivalFemaleHumansMaleMiceMice, Inbred C57BLRemyelinationVascular Endothelial Growth Factor CVascular Endothelial Growth Factor Cbrain myelindemyelinationimmune cellsmeningeal lymphatic vesselsmultiple sclerosisneuroinflammationoligodendrocytesoxidative stressremyelinationvascular endothelial growth factor C

Identifiers

PMID39217987
PMCPMC11464205

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.